Shares of IDEAYA Biosciences (NASDAQ:IDYA) have been assigned a consensus broker rating score of 1.67 (Buy) from the three brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation and two have given a strong buy recommendation to the company.
Brokerages have set a 1 year consensus price target of $16.33 for the company and are predicting that the company will post ($0.63) EPS for the current quarter, according to Zacks. Zacks has also given IDEAYA Biosciences an industry rank of 48 out of 256 based on the ratings given to its competitors.
Several research firms have recently commented on IDYA. Citigroup decreased their price target on shares of Thor Industries from $78.00 to $70.00 in a research note on Monday, June 17th. JPMorgan Chase & Co. decreased their price target on shares of from GBX 97 ($1.27) to GBX 89 ($1.16) and set a “neutral” rating on the stock in a research note on Monday, June 17th. Finally, Jefferies Financial Group decreased their price target on shares of Huntsman from $33.00 to $30.00 and set a “buy” rating on the stock in a research note on Monday, June 17th.
In other IDEAYA Biosciences news, major shareholder Alexandria Venture Investments acquired 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The shares were acquired at an average cost of $10.00 per share, for a total transaction of $500,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of IDYA traded down $0.39 during mid-day trading on Tuesday, hitting $6.82. 27,255 shares of the company traded hands, compared to its average volume of 62,120. IDEAYA Biosciences has a one year low of $6.69 and a one year high of $16.90. The business has a 50-day simple moving average of $9.48.
IDEAYA Biosciences Company Profile
IDEAYA Biosciences, Inc, an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.
Recommended Story: Compound Interest and Why It Matters When Investing
Get a free copy of the Zacks research report on IDEAYA Biosciences (IDYA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.